BLAINJECTIONINJECTABLE
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
RUXIENCE (rituximab-pvvr) by Pfizer is cd20-directed antibody interactions [moa]. Approved for cd20-directed cytolytic antibody [epc]. First approved in 2019.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RUXIENCE (rituximab-pvvr) is a CD20-directed cytolytic monoclonal antibody approved by the FDA in July 2019 as a Pfizer biosimilar to reference rituximab. It is indicated for CD20-positive B-cell malignancies and autoimmune conditions, working by binding to CD20 antigen on B cells and triggering cell death. The drug is administered via intravenous injection.
$0.017BPart D
PeakRUXIENCE is in peak commercial phase with $17M in Part D spending (2023), indicating established market presence; team size and growth opportunities depend on Pfizer's biosimilar portfolio strategy amid intense CD20 competition.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RUXIENCE offers stable commercial career opportunities in a mature, peak-revenue phase product within Pfizer's biosimilar portfolio. Roles focus on competitive market positioning, payer negotiations, and erosion mitigation against both reference and competing biosimilars rather than clinical innovation or launch-phase growth.
Brand Manager
Worked on RUXIENCE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.